Our rare disease portfolio features innovative diagnostic agents engineered to address a variety of rare and disabling childhood conditions. These novel radiopharmaceuticals are designed to facilitate earlier, more precise diagnosis, and enable tailored treatment plans that can dramatically improve quality of life for affected children and their families.

By targeting critical unmet needs, we are committed to transforming the standard of care for numerous rare pediatric diseases. Our diagnostic tools empower clinicians to detect these complex conditions sooner, while our personalized therapeutic approaches offer new hope for improved outcomes and enhanced well-being for young patients.

Through continuous innovation, we strive to make a meaningful difference in the lives of children and their loved ones impacted by devastating rare diseases.